Literature DB >> 22453095

Monoclonal antibodies directed against human FcRn and their applications.

Gregory J Christianson1, Victor Z Sun1, Shreeram Akilesh2, Emanuele Pesavento3, Gabriele Proetzel1, Derry C Roopenian1.   

Abstract

The MHC class I-like Fc receptor (FcRn) is an intracellular trafficking Fc receptor that is uniquely responsible for the extended serum half-life of antibodies of the IgG subclass and their ability to transport across cellular barriers. By performing these functions, FcRn affects numerous facets of antibody biology and pathobiology. Its critical role in controlling IgG pharmacokinetics has been leveraged for the design of therapeutic antibodies and related biologics. FcRn also traffics serum albumin and is responsible for the enhanced pharmacokinetic properties of albumin-conjugated therapeutics. The understanding of FcRn and its therapeutic applications has been limited by a paucity of reliable serological reagents against human FcRn. Here, we describe the properties of a new panel of highly specific monoclonal antibodies (mAbs) directed against human FcRn with diverse epitope specificities. We show that this antibody panel can be used to study the tissue expression pattern of human FcRn, to selectively block IgG and serum albumin binding to human FcRn in vitro and to inhibit FcRn function in vivo. This mAb panel provides a powerful resource for probing the biology of human FcRn and for the evaluation of therapeutic FcRn blockade strategies.

Entities:  

Keywords:  FcRn; IgG; albumin; monoclonal antibody; therapy

Mesh:

Substances:

Year:  2012        PMID: 22453095      PMCID: PMC3361656          DOI: 10.4161/mabs.4.2.19397

Source DB:  PubMed          Journal:  MAbs        ISSN: 1942-0862            Impact factor:   5.857


  36 in total

1.  Crystal structure at 2.8 A of an FcRn/heterodimeric Fc complex: mechanism of pH-dependent binding.

Authors:  W L Martin; A P West; L Gan; P J Bjorkman
Journal:  Mol Cell       Date:  2001-04       Impact factor: 17.970

2.  Increased clearance of IgG in mice that lack beta 2-microglobulin: possible protective role of FcRn.

Authors:  E J Israel; D F Wilsker; K C Hayes; D Schoenfeld; N E Simister
Journal:  Immunology       Date:  1996-12       Impact factor: 7.397

3.  Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies.

Authors:  R J Ober; C G Radu; V Ghetie; E S Ward
Journal:  Int Immunol       Date:  2001-12       Impact factor: 4.823

4.  Crystal structure of the complex of rat neonatal Fc receptor with Fc.

Authors:  W P Burmeister; A H Huber; P J Bjorkman
Journal:  Nature       Date:  1994-11-24       Impact factor: 49.962

5.  Characterization and localization of the neonatal Fc receptor in adult human kidney.

Authors:  Jean-Philippe Haymann; Jean-Pierre Levraud; Sandrine Bouet; Vincent Kappes; Jacqueline Hagège; Genevieve Nguyen; Yichun Xu; Eric Rondeau; Jean-Daniel Sraer
Journal:  J Am Soc Nephrol       Date:  2000-04       Impact factor: 10.121

6.  The MHC class I-like IgG receptor controls perinatal IgG transport, IgG homeostasis, and fate of IgG-Fc-coupled drugs.

Authors:  Derry C Roopenian; Gregory J Christianson; Thomas J Sproule; Aaron C Brown; Shreeram Akilesh; Nadja Jung; Stefka Petkova; Lia Avanessian; Eun Young Choi; Daniel J Shaffer; Peter A Eden; Clark L Anderson
Journal:  J Immunol       Date:  2003-04-01       Impact factor: 5.422

7.  beta2-microglobulin dependence of the lupus-like autoimmune syndrome of MRL-lpr mice.

Authors:  G J Christianson; R L Blankenburg; T M Duffy; D Panka; J B Roths; A Marshak-Rothstein; D C Roopenian
Journal:  J Immunol       Date:  1996-06-15       Impact factor: 5.422

8.  The MHC class I-like Fc receptor promotes humorally mediated autoimmune disease.

Authors:  Shreeram Akilesh; Stefka Petkova; Thomas J Sproule; Daniel J Shaffer; Gregory J Christianson; Derry Roopenian
Journal:  J Clin Invest       Date:  2004-05       Impact factor: 14.808

9.  Abnormally short serum half-lives of IgG in beta 2-microglobulin-deficient mice.

Authors:  V Ghetie; J G Hubbard; J K Kim; M F Tsen; Y Lee; E S Ward
Journal:  Eur J Immunol       Date:  1996-03       Impact factor: 5.532

10.  Structure-based mutagenesis reveals the albumin-binding site of the neonatal Fc receptor.

Authors:  Jan Terje Andersen; Bjørn Dalhus; Jason Cameron; Muluneh Bekele Daba; Andrew Plumridge; Leslie Evans; Stephan O Brennan; Kristin Støen Gunnarsen; Magnar Bjørås; Darrell Sleep; Inger Sandlie
Journal:  Nat Commun       Date:  2012-01-03       Impact factor: 14.919

View more
  21 in total

1.  Fc Engineering of Human IgG1 for Altered Binding to the Neonatal Fc Receptor Affects Fc Effector Functions.

Authors:  Algirdas Grevys; Malin Bern; Stian Foss; Diane Bryant Bratlie; Anders Moen; Kristin Støen Gunnarsen; Audun Aase; Terje Einar Michaelsen; Inger Sandlie; Jan Terje Andersen
Journal:  J Immunol       Date:  2015-04-22       Impact factor: 5.422

2.  Hepatic FcRn regulates albumin homeostasis and susceptibility to liver injury.

Authors:  Michal Pyzik; Timo Rath; Timothy T Kuo; Sanda Win; Kristi Baker; Jonathan J Hubbard; Rosa Grenha; Amit Gandhi; Thomas D Krämer; Adam R Mezo; Zachary S Taylor; Kevin McDonnell; Vicki Nienaber; Jan Terje Andersen; Atsushi Mizoguchi; Laurence Blumberg; Shalaka Purohit; Susan D Jones; Greg Christianson; Wayne I Lencer; Inger Sandlie; Neil Kaplowitz; Derry C Roopenian; Richard S Blumberg
Journal:  Proc Natl Acad Sci U S A       Date:  2017-03-22       Impact factor: 11.205

3.  Cross-Reactive Dengue Virus Antibodies Augment Zika Virus Infection of Human Placental Macrophages.

Authors:  Matthew G Zimmerman; Kendra M Quicke; Justin T O'Neal; Nitin Arora; Deepa Machiah; Lalita Priyamvada; Robert C Kauffman; Emery Register; Oluwaseyi Adekunle; Dominika Swieboda; Erica L Johnson; Sarah Cordes; Lisa Haddad; Rana Chakraborty; Carolyn B Coyne; Jens Wrammert; Mehul S Suthar
Journal:  Cell Host Microbe       Date:  2018-11-14       Impact factor: 21.023

4.  Dissection of the neonatal Fc receptor (FcRn)-albumin interface using mutagenesis and anti-FcRn albumin-blocking antibodies.

Authors:  Kine Marita Knudsen Sand; Bjørn Dalhus; Gregory J Christianson; Malin Bern; Stian Foss; Jason Cameron; Darrell Sleep; Magnar Bjørås; Derry C Roopenian; Inger Sandlie; Jan Terje Andersen
Journal:  J Biol Chem       Date:  2014-04-24       Impact factor: 5.157

5.  Hematopoietic cells as site of first-pass catabolism after subcutaneous dosing and contributors to systemic clearance of a monoclonal antibody in mice.

Authors:  Wolfgang F Richter; Gregory J Christianson; Nicolas Frances; Hans Peter Grimm; Gabriele Proetzel; Derry C Roopenian
Journal:  MAbs       Date:  2018-05-09       Impact factor: 5.857

6.  Regulation of the Human Fc-Neonatal Receptor alpha-Chain Gene FCGRT by MicroRNA-3181.

Authors:  Daniel C Ferguson; Javier G Blanco
Journal:  Pharm Res       Date:  2018-01-04       Impact factor: 4.200

7.  Expression of neonatal Fc receptor in the eye.

Authors:  Michael B Powner; Jenny A G McKenzie; Gregory J Christianson; Derry C Roopenian; Marcus Fruttiger
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-03-19       Impact factor: 4.799

8.  Development of a novel prostate apoptosis response-4 (Par-4) protein entity with an extended duration of action for therapeutic treatment of cancer.

Authors:  Kyungbo Kim; Pereira Araujo; Nikhil Hebbar; Ziyuan Zhou; Xirong Zheng; Fang Zheng; Vivek M Rangnekar; Chang-Guo Zhan
Journal:  Protein Eng Des Sel       Date:  2019-12-13       Impact factor: 1.650

Review 9.  Rational clinical trial design for antibody mediated renal allograft injury.

Authors:  Shaifali Sandal; Martin S Zand
Journal:  Front Biosci (Landmark Ed)       Date:  2015-01-01

10.  FcRn augments induction of tissue factor activity by IgG-containing immune complexes.

Authors:  Douglas B Cines; Sergei Zaitsev; Lubica Rauova; Ann H Rux; Victoria Stepanova; Sriram Krishnaswamy; Amrita Sarkar; M Anna Kowalska; Guohua Zhao; Alan E Mast; Laurence J Blumberg; Keith R McCrae; Mortimer Poncz; Jonathan J Hubbard; Michal Pyzik; Richard S Blumberg
Journal:  Blood       Date:  2020-06-04       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.